Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBITO phase III trial in high-risk HR-deficient stage III HER2-negative breast cancer
NL-OMON60727Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olaparib, capecitabine, cyclophosphamide, thiotepa, carboplatin and 2 more in breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall survival. Started Jan 2017; status: recruiting.
02
Drugs
olaparibcapecitabinecyclophosphamidethiotepacarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60727.